|
DE69739172D1
(de)
|
1996-08-08 |
2009-01-29 |
Amylin Pharmaceuticals Inc |
Regulation gastrointestinaler beweglichkeit
|
|
PT1629849E
(pt)
|
1997-01-07 |
2013-07-09 |
Amylin Pharmaceuticals Llc |
Composições farmacêuticas que compreendem exendinas e seus agonistas
|
|
DK1019077T4
(da)
*
|
1997-08-08 |
2011-03-07 |
Amylin Pharmaceuticals Inc |
Hidtil ukendte exendinagonistforbindelser
|
|
US7157555B1
(en)
*
|
1997-08-08 |
2007-01-02 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist compounds
|
|
JP2003522721A
(ja)
*
|
1997-11-14 |
2003-07-29 |
アミリン・ファーマシューティカルズ，インコーポレイテッド |
新規なエキセンジンアゴニスト化合物
|
|
EP1938830A1
(en)
*
|
1997-11-14 |
2008-07-02 |
Amylin Pharmaceuticals, Inc. |
Novel exendin agonist compounds
|
|
JP2001523688A
(ja)
†
|
1997-11-14 |
2001-11-27 |
アミリン・ファーマシューティカルズ，インコーポレイテッド |
新規エキセンジン・アゴニスト化合物
|
|
EP1941900A1
(en)
*
|
1997-11-14 |
2008-07-09 |
Amylin Pharmaceuticals, Inc. |
Novel exendin agonist compounds
|
|
US7220721B1
(en)
|
1997-11-14 |
2007-05-22 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist peptides
|
|
EP1840134B1
(en)
|
1998-02-27 |
2016-04-13 |
Novo Nordisk A/S |
GLP-1 derivatives
|
|
WO1999043708A1
(en)
|
1998-02-27 |
1999-09-02 |
Novo Nordisk A/S |
Glp-1 derivatives of glp-1 and exendin with protracted profile of action
|
|
NZ508823A
(en)
|
1998-06-12 |
2003-10-31 |
Amylin Pharmaceuticals Inc |
Glucagon-like peptide-1 improves beta-cell response to glucose in subjects with impaired glucose tolerance or increased risk of a cardiovascular or cerebrovascular event
|
|
AU5027299A
(en)
|
1998-07-31 |
2000-02-28 |
Novo Nordisk A/S |
Use of glp-1 and analogues for preventing type ii diabetes
|
|
CN101181236A
(zh)
|
1999-01-14 |
2008-05-21 |
安米林药品公司 |
新型exendin激动剂制剂及其给药方法
|
|
EP1658856B1
(en)
*
|
1999-01-14 |
2010-03-17 |
Amylin Pharmaceuticals, Inc. |
Exendins for glucagon suppression
|
|
US7399489B2
(en)
|
1999-01-14 |
2008-07-15 |
Amylin Pharmaceuticals, Inc. |
Exendin analog formulations
|
|
US6605648B1
(en)
*
|
1999-04-06 |
2003-08-12 |
Phillips Plastics Corporation |
Sinterable structures and method
|
|
US6924264B1
(en)
*
|
1999-04-30 |
2005-08-02 |
Amylin Pharmaceuticals, Inc. |
Modified exendins and exendin agonists
|
|
EP1175443A1
(en)
|
1999-04-30 |
2002-01-30 |
Amylin Pharmaceuticals, Inc. |
Modified exendins and exendin agonists
|
|
US6514500B1
(en)
|
1999-10-15 |
2003-02-04 |
Conjuchem, Inc. |
Long lasting synthetic glucagon like peptide {GLP-!}
|
|
US20090175821A1
(en)
*
|
1999-05-17 |
2009-07-09 |
Bridon Dominique P |
Modified therapeutic peptides with extended half-lives in vivo
|
|
SI1180121T1
(en)
*
|
1999-05-17 |
2004-04-30 |
Conjuchem, Inc. |
Long lasting insulinotropic peptides
|
|
US6528486B1
(en)
|
1999-07-12 |
2003-03-04 |
Zealand Pharma A/S |
Peptide agonists of GLP-1 activity
|
|
US6844321B2
(en)
|
2000-01-31 |
2005-01-18 |
Novo Nordisk A/S |
Crystallization of a GLP-1 analogue
|
|
DE60114996T2
(de)
|
2000-03-08 |
2006-08-10 |
Novo Nordisk A/S |
Senkung des serum cholesterols
|
|
EP2186824A3
(en)
*
|
2000-12-13 |
2010-09-22 |
Eli Lilly & Company |
Chronic treatment regimen using glucagon-like insulinotropic peptides
|
|
ATE396202T1
(de)
*
|
2001-02-16 |
2008-06-15 |
Conjuchem Biotechnologies Inc |
Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen
|
|
JP2005501058A
(ja)
|
2001-07-31 |
2005-01-13 |
ザ ガバメント オブ ザ ユナイテッドステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ ザ ナショナル インステ |
Ｇｌｐ−１、ｅｘｅｎｄｉｎ−４、そのペプチド・アナログ及びその使用
|
|
BR0314996A
(pt)
*
|
2002-10-02 |
2005-08-09 |
Zealand Pharma As |
Composição, composição farmaceuticamente aceitável, método para produzir a composição, métodos para estabilizar a exendina-4 (1-39) ou uma sua variante, derivado ou análogo contra a degradação, antes, durante ou após o uso pretendido, para tratar doenças, para tratar de estados de doenças associados com nìveis elevados de glicose do sangue, para a regulação dos nìveis de glicose do sangue, para a regulação do esvaziamento gástrico, para estimular a liberação de insulina em um mamìfero para reduzir o nìvel de glicose do sangue em um mamìfero, para reduzir o nìvel de lipìdeos plasmáticos em um mamìfero, para reduzir a mortalidade e a morbidez após o infarto miocárdico em um mamìfero, para estimular a liberação de insulina em um mamìfero, e para produzir uma exendina (1-39) estabilizada, e, exendina (1-39) estabilizada
|
|
WO2004036186A2
(en)
*
|
2002-10-17 |
2004-04-29 |
Alkermes Controlled Therapeutics, Inc. Ii |
Microencapsulation and sustained release of biologically active polypeptides
|
|
US7731947B2
(en)
|
2003-11-17 |
2010-06-08 |
Intarcia Therapeutics, Inc. |
Composition and dosage form comprising an interferon particle formulation and suspending vehicle
|
|
ES2425221T3
(es)
*
|
2003-05-30 |
2013-10-14 |
Amylin Pharmaceuticals, Llc |
Nuevos métodos y composiciones para suministro por vía transmucosa potenciado de péptidos y proteínas
|
|
US8263084B2
(en)
|
2003-11-13 |
2012-09-11 |
Hanmi Science Co., Ltd |
Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
|
|
KR101135244B1
(ko)
|
2007-11-29 |
2012-04-24 |
한미사이언스 주식회사 |
인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물
|
|
PT1687019T
(pt)
|
2003-11-20 |
2018-02-26 |
Novo Nordisk As |
Formulações de péptidos que contêm polietileno glicol que são ótimas para produção e para utilização em dispositivos de injeção
|
|
WO2005056036A2
(en)
|
2003-12-09 |
2005-06-23 |
Novo Nordisk A/S |
Regulation of food preference using glp-1 agonists
|
|
US20050143303A1
(en)
*
|
2003-12-26 |
2005-06-30 |
Nastech Pharmaceutical Company Inc. |
Intranasal administration of glucose-regulating peptides
|
|
US20060074025A1
(en)
*
|
2003-12-26 |
2006-04-06 |
Nastech Pharmaceutical Company Inc. |
Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability
|
|
US20080318837A1
(en)
*
|
2003-12-26 |
2008-12-25 |
Nastech Pharmaceutical Company Inc. |
Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide
|
|
US20060210614A1
(en)
*
|
2003-12-26 |
2006-09-21 |
Nastech Pharmaceutical Company Inc. |
Method of treatment of a metabolic disease using intranasal administration of exendin peptide
|
|
CA2564031A1
(en)
*
|
2004-04-23 |
2005-11-03 |
Conjuchem Biotechnologies Inc. |
Method for the purification of albumin conjugates
|
|
EP1758575A1
(en)
|
2004-06-11 |
2007-03-07 |
Novo Nordisk A/S |
Counteracting drug-induced obesity using glp-1 agonists
|
|
DE102004043153B4
(de)
*
|
2004-09-03 |
2013-11-21 |
Philipps-Universität Marburg |
Erfindung betreffend GLP-1 und Exendin
|
|
AU2012202855B2
(en)
*
|
2004-09-03 |
2015-02-26 |
Philipps-Universitat Marburg |
GLP-1 and exendin related invention
|
|
CN100535003C
(zh)
*
|
2004-09-06 |
2009-09-02 |
上海华谊生物技术有限公司 |
Exendin 4的类似物
|
|
CA2603630C
(en)
*
|
2005-01-14 |
2015-06-09 |
Wuxi Grandchamp Pharmaceutical Technology Co., Ltd. |
Modified exendins and uses thereof
|
|
US8716221B2
(en)
|
2005-01-14 |
2014-05-06 |
Wuxi Grandchamp Pharmaceutical Technology Co., Ltd. |
Modified exendins and uses thereof
|
|
US11246913B2
(en)
|
2005-02-03 |
2022-02-15 |
Intarcia Therapeutics, Inc. |
Suspension formulation comprising an insulinotropic peptide
|
|
WO2006083761A2
(en)
|
2005-02-03 |
2006-08-10 |
Alza Corporation |
Solvent/polymer solutions as suspension vehicles
|
|
CN100429227C
(zh)
*
|
2005-06-29 |
2008-10-29 |
常州制药厂有限公司 |
Exendin4多肽片段
|
|
CA2628241C
(en)
|
2005-11-07 |
2016-02-02 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting physiological solubility and stability
|
|
US8039432B2
(en)
*
|
2005-11-09 |
2011-10-18 |
Conjuchem, Llc |
Method of treatment of diabetes and/or obesity with reduced nausea side effect
|
|
WO2007061434A2
(en)
*
|
2005-11-10 |
2007-05-31 |
Nastech Pharmaceutical Company Inc. |
A pharmaceutical formulation of glp-1 and its use for treating a metabolic syndrome
|
|
WO2007067964A2
(en)
*
|
2005-12-08 |
2007-06-14 |
Nastech Pharmaceutical Company Inc. |
Mucosal delivery of stabilized formulations of exendin
|
|
EP1976876A4
(en)
*
|
2005-12-22 |
2010-01-13 |
Conjuchem Biotechnologies Inc |
PROCESS FOR PRODUCING PREFORMED ALBUMIN CONJUGATES AND THERAPEUTIC AGENT
|
|
KR101106510B1
(ko)
|
2006-05-30 |
2012-01-20 |
인타르시아 세라퓨틱스 인코포레이티드 |
투피스, 내부채널 삼투압 전달 시스템 유동 조절기
|
|
CA2670821C
(en)
|
2006-08-09 |
2012-05-15 |
Intarcia Therapeutics, Inc. |
Osmotic delivery systems and piston assemblies
|
|
RU2413528C2
(ru)
|
2007-01-18 |
2011-03-10 |
Открытое Акционерное Общество "Валента Фармацевтика" |
Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения
|
|
MX2009008241A
(es)
|
2007-02-15 |
2009-10-08 |
Univ Indiana Res & Tech Corp |
Co-agonistas de receptor de glucagon/glp-1.
|
|
CA2683610C
(en)
*
|
2007-04-23 |
2013-01-08 |
Intarcia Therapeutics, Inc. |
Suspension formulations of insulinotropic peptides and uses thereof
|
|
KR100746658B1
(ko)
|
2007-04-23 |
2007-08-06 |
성균관대학교산학협력단 |
소수성 담즙산이 접합된 엑센딘-4 유도체, 이의 제조방법및 이를 포함하는 약학 조성물
|
|
JP2009019027A
(ja)
|
2007-07-16 |
2009-01-29 |
Hanmi Pharmaceutical Co Ltd |
アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
|
|
JP2010538069A
(ja)
*
|
2007-09-07 |
2010-12-09 |
イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ |
エキセンディン−４およびエキセンディン−３の類似体
|
|
JP5771005B2
(ja)
|
2007-10-30 |
2015-08-26 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ |
グルカゴンアンタゴニスト及びｇｌｐ−１アゴニスト活性を示す化合物
|
|
US20090186819A1
(en)
*
|
2007-12-11 |
2009-07-23 |
Marieve Carrier |
Formulation of insulinotropic peptide conjugates
|
|
WO2009102467A2
(en)
|
2008-02-13 |
2009-08-20 |
Intarcia Therapeutics, Inc. |
Devices, formulations, and methods for delivery of multiple beneficial agents
|
|
US20090221453A1
(en)
*
|
2008-02-29 |
2009-09-03 |
Sumitra Mukhopadhyay |
Treatment Fluid With Oxidizer Breaker System and Method
|
|
TWI474835B
(zh)
|
2008-06-17 |
2015-03-01 |
Univ Indiana Res & Tech Corp |
用於治療代謝病症及肥胖症之基於ｇｉｐ之混合激動劑
|
|
EP2300037B1
(en)
|
2008-06-17 |
2016-03-30 |
Indiana University Research and Technology Corporation |
Glucagon/glp-1 receptor co-agonists
|
|
PT3228320T
(pt)
|
2008-10-17 |
2020-03-26 |
Sanofi Aventis Deutschland |
Combinação de uma insulina e de um agonista do glp-1
|
|
CN102271775A
(zh)
|
2008-12-08 |
2011-12-07 |
诺沃-诺迪斯克有限公司 |
多肽的逆流提纯
|
|
RU2550696C2
(ru)
|
2008-12-19 |
2015-05-10 |
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн |
Основанные на амидах пролекарства пептидов глюкагонового надсемейства
|
|
CN101463078B
(zh)
*
|
2009-01-12 |
2011-07-27 |
华东师范大学 |
一种Exendin-4衍生物及其固相化学合成
|
|
WO2010148089A1
(en)
|
2009-06-16 |
2010-12-23 |
Indiana University Research And Technology Corporation |
Gip receptor-active glucagon compounds
|
|
KR101853606B1
(ko)
|
2009-07-06 |
2018-05-03 |
사노피-아벤티스 도이칠란트 게엠베하 |
메티오닌을 함유하는 수성 인슐린 제제
|
|
MX378797B
(es)
|
2009-09-28 |
2025-03-10 |
Intarcia Therapeutics Inc |
Establecimiento y/o terminacion rapidos de suministro de estado estable sustancial de farmaco.
|
|
KR101337322B1
(ko)
|
2009-11-13 |
2013-12-06 |
사노피-아벤티스 도이칠란트 게엠베하 |
Ｇｌｐ-1 효능제 및 메티오닌을 포함하는 약제학적 조성물
|
|
DK2498802T3
(en)
|
2009-11-13 |
2015-04-13 |
Sanofi Aventis Deutschland |
Pharmaceutical composition comprising a GLP-1 agonist, insulin and a methionine
|
|
WO2011064316A2
(en)
|
2009-11-25 |
2011-06-03 |
Paolo Botti |
Mucosal delivery of peptides
|
|
US8703701B2
(en)
*
|
2009-12-18 |
2014-04-22 |
Indiana University Research And Technology Corporation |
Glucagon/GLP-1 receptor co-agonists
|
|
EP2528618A4
(en)
|
2010-01-27 |
2015-05-27 |
Univ Indiana Res & Tech Corp |
GLUCAGON ANTAGONISTE AND GIP AGONISTS CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISEASES AND ADIPOSITAS
|
|
CN102770440A
(zh)
|
2010-03-01 |
2012-11-07 |
诺沃—诺迪斯克有限公司 |
纯化肽的制备性rp-hplc方法
|
|
US9168288B2
(en)
|
2010-04-09 |
2015-10-27 |
Mount Sinai Hospital |
Methods for treating disorders of the gastrointestinal tract using a GLP-1 agonist
|
|
CA2797133C
(en)
|
2010-04-27 |
2019-08-06 |
Zealand Pharma A/S |
Peptide conjugates of glp-1 receptor agonists and gastrin and their use
|
|
ES2606554T3
(es)
|
2010-08-30 |
2017-03-24 |
Sanofi-Aventis Deutschland Gmbh |
Uso de AVE0010 para la fabricación de un medicamento para el tratamiento de la diabetes mellitus de tipo 2
|
|
WO2012088116A2
(en)
|
2010-12-22 |
2012-06-28 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting gip receptor activity
|
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
|
CN103918055B
(zh)
|
2011-03-31 |
2016-08-17 |
Dh科技发展私人贸易有限公司 |
用于校准质谱仪的组合物、方法和试剂盒
|
|
US9821032B2
(en)
|
2011-05-13 |
2017-11-21 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
|
|
CN103857408B
(zh)
|
2011-06-22 |
2017-04-12 |
印第安那大学科技研究公司 |
胰高血糖素/glp‑1受体协同激动剂
|
|
MX2013015168A
(es)
|
2011-06-22 |
2014-03-31 |
Univ Indiana Res & Tech Corp |
Co-agonista del receptor de glucagon/glp-1.
|
|
PL2750699T3
(pl)
|
2011-08-29 |
2015-12-31 |
Sanofi Aventis Deutschland |
Kombinacja farmaceutyczna do stosowania w kontroli glikemii u pacjentów z cukrzycą typu 2
|
|
AR087744A1
(es)
|
2011-09-01 |
2014-04-16 |
Sanofi Aventis Deutschland |
Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
|
|
TW201326194A
(zh)
|
2011-11-03 |
2013-07-01 |
Zealand Pharma As |
Ｇｌｐ－１胃泌素受體促效劑肽結合物
|
|
CN104244981A
(zh)
|
2011-12-09 |
2014-12-24 |
诺和诺德A/S |
Glp-1激动剂
|
|
WO2013170636A1
(zh)
|
2012-05-18 |
2013-11-21 |
爱德迪安（北京）生物技术有限公司 |
用于糖尿病治疗的蛋白、蛋白缀合物及其应用
|
|
US9340600B2
(en)
|
2012-06-21 |
2016-05-17 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting GIP receptor activity
|
|
MX356957B
(es)
|
2012-07-23 |
2018-06-20 |
Zealand Pharma As |
Analogos del glucagon.
|
|
TWI608013B
(zh)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
升糖素類似物
|
|
KR20140088837A
(ko)
|
2013-01-03 |
2014-07-11 |
한미약품 주식회사 |
Ｎ-말단 전하가 변형된 인슐린 분비 펩티드 유도체
|
|
TWI641381B
(zh)
|
2013-02-04 |
2018-11-21 |
法商賽諾菲公司 |
胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
|
|
LT3057984T
(lt)
|
2013-10-17 |
2018-12-27 |
Zealand Pharma A/S |
Acilinti gliukagono analogai
|
|
US9988429B2
(en)
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
|
AU2014345569B2
(en)
|
2013-11-06 |
2020-08-13 |
Zealand Pharma A/S |
GIP-GLP-1 dual agonist compounds and methods
|
|
KR102310392B1
(ko)
|
2013-11-06 |
2021-10-13 |
질랜드 파마 에이/에스 |
글루카곤-ｇｌｐ-1-ｇｉｐ 삼원 효능제 화합물
|
|
CN112043835B
(zh)
|
2013-12-06 |
2022-10-21 |
韩捷 |
用于含氮和羟基的药物的生物可逆引入基团
|
|
EP3091965A1
(en)
|
2014-01-09 |
2016-11-16 |
Sanofi |
Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
|
|
CN112957455A
(zh)
|
2014-01-09 |
2021-06-15 |
赛诺菲 |
胰岛素类似物和/或胰岛素衍生物的稳定化药物制剂
|
|
SG11201604706TA
(en)
|
2014-01-09 |
2016-07-28 |
Sanofi Sa |
Stabilized pharmaceutical formulations of insulin aspart
|
|
US9889085B1
(en)
|
2014-09-30 |
2018-02-13 |
Intarcia Therapeutics, Inc. |
Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
|
|
RU2716985C2
(ru)
|
2014-10-29 |
2020-03-17 |
Зилэнд Фарма А/С |
Соединения-агонисты gip и способы
|
|
AU2015359376B2
(en)
|
2014-12-12 |
2021-09-09 |
Sanofi-Aventis Deutschland Gmbh |
Insulin glargine/lixisenatide fixed ratio formulation
|
|
TWI748945B
(zh)
|
2015-03-13 |
2021-12-11 |
德商賽諾菲阿凡提斯德意志有限公司 |
第２型糖尿病病患治療
|
|
TW201705975A
(zh)
|
2015-03-18 |
2017-02-16 |
賽諾菲阿凡提斯德意志有限公司 |
第２型糖尿病病患之治療
|
|
JP6989385B2
(ja)
|
2015-04-16 |
2022-01-05 |
ジーランド ファーマ アクティーゼルスカブ |
アシル化グルカゴン類似体
|
|
CN113598842A
(zh)
|
2015-06-03 |
2021-11-05 |
因塔西亚制药公司 |
植入物放置和移除系统
|
|
CN105753963B
(zh)
*
|
2016-04-13 |
2019-08-30 |
中国药科大学 |
高活性艾塞那肽类似物及其医药应用
|
|
KR102574993B1
(ko)
|
2016-05-16 |
2023-09-06 |
인타르시아 세라퓨틱스 인코포레이티드 |
글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
|
|
USD840030S1
(en)
|
2016-06-02 |
2019-02-05 |
Intarcia Therapeutics, Inc. |
Implant placement guide
|
|
USD860451S1
(en)
|
2016-06-02 |
2019-09-17 |
Intarcia Therapeutics, Inc. |
Implant removal tool
|
|
SG10201911851VA
(en)
|
2016-12-09 |
2020-02-27 |
Zealand Pharma As |
Acylated glp-1/glp-2 dual agonists
|
|
WO2018129058A1
(en)
|
2017-01-03 |
2018-07-12 |
Intarcia Therapeutics, Inc. |
Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
|
|
CN109485720A
(zh)
*
|
2017-09-11 |
2019-03-19 |
中国药科大学 |
口服降血糖多肽、其脂肪酸修饰衍生物以及用途
|
|
CA3123979A1
(en)
|
2018-12-21 |
2020-06-25 |
Jiangsu Hengrui Medicine Co., Ltd. |
Bispecific protein
|
|
CN116606367A
(zh)
*
|
2022-05-31 |
2023-08-18 |
南京盛德瑞尔医药科技有限公司 |
长效Exendin-9-39及其在低血糖治疗中的应用和作为治疗低血糖的药物
|